Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03730311 |
Recruitment Status : Unknown
Verified May 2019 by Viriom.
Recruitment status was: Not yet recruiting
First Posted : November 5, 2018
Last Update Posted : May 20, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Elpida Drug: placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Double (Participant, Investigator) |
Masking Description: | Double-blind study |
Primary Purpose: | Treatment |
Official Title: | Phase Ib, Single-Centre, Placebo-Controlled Randomised Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers |
Estimated Study Start Date : | May 2019 |
Estimated Primary Completion Date : | November 2019 |
Estimated Study Completion Date : | December 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Elpida 120 mg once weekly
elsulfavirine 120mg or placebo orally once weekly for 4 weeks
|
Drug: Elpida
elsulfavirine, capsules
Other Names:
Drug: placebo placebo |
Experimental: Elpida 200 mg once weekly
elsulfavirine 200mg or placebo orally once weekly for 4 weeks
|
Drug: Elpida
elsulfavirine, capsules
Other Names:
Drug: placebo placebo |
Experimental: Elpida 280 mg once weekly
elsulfavirine 280mg or placebo orally once weekly for 4 weeks
|
Drug: Elpida
elsulfavirine, capsules
Other Names:
Drug: placebo placebo |
- Incidence of AEs and SAEs [ Time Frame: 36 days ]Incidence of AEs and SAEs
- elsulfavirine plasma concentration [ Time Frame: 36 days ]elsulfavirine plasma concentration
- VM1500A plasma concentration [ Time Frame: 36 days ]active metabolite plasma concentration
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy males or females aged between 18-40 years.
- Willing and able to complete all study procedures, visits and restrictions.
- Capable of giving written informed consent.
- Has been determined healthy by medical history, physical and vital signs examinations.
- Has normal results for the following screening tests: complete blood count (CBC), sodium, potassium, blood urea nitrogen (BUN), serum creatinine, fasting blood sugar (FBS), creatine kinase, total calcium, cholesterol, triglyceride, total protein, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and urinalysis.
- Females of reproductive potential (defined as women who have not been postmenopausal for at least 24 consecutive months [i.e., who have had menses within the preceding 24 months], or women who have not undergone surgical sterilization; specifically hysterectomy, salpingotomy, bilateral oophorectomy, and/or tubal ligation), must have a negative serum or urine pregnancy test with a sensitivity of at least 40 mIU/mL at Screening and prior to drug dosing on Day 1.
-
All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the participant must agree to use two reliable methods of contraception simultaneously while receiving study treatment and for 6 months after stopping study drug. Subjects must either be abstinent or a combination of TWO of the following methods MUST be used appropriately:
- Condoms (male or female) with or without a spermicidal agent;
- Diaphragm or cervical cap with spermicide;
- Intrauterine device (IUD);
- Hormonal-based contraception. Participants who are not of reproductive potential (women who have been postmenopausal for at least 24 consecutive months or have undergone hysterectomy, salpingotomy, bilateral oophorectomy, and/or tubal ligation or men who have documented azoospermia) are eligible without requiring the use of contraceptives. Acceptable documentation of sterilization, menopause or male partner's azoospermia must be provided; serum follicle stimulating hormone (FSH) measurement can be used to document menopausal range.
Exclusion Criteria:
- Hepatic or kidney disorders or any other disease or disorder which may in the opinion of the Investigator interfere with the results of the study or threaten the health of volunteers.
- Clinically significant ECG abnormality according to ECG exam at Screening, subject's medical history or family history judged by the Investigator that the presence of, or an increased risk of cardiac abnormality.
- Positive result for HIV, HCV or HBV at Screening.
- Positive result for illicit drugs screen (opiates, amphetamines, cannabinoids or cocaine) or alcohol screen at Screening.
- Active alcohol or and/or drug abuse that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Received the excluded medications (as shown in Appendix 3) within 14 days or 28 days prior to the first dose of study drug, or within the 5 half-lives of individual medication, whichever is longer.
- Participated in a clinical study and received any investigational drug or vaccine or medical device within 90 days prior to the first dose of study drug.
- Pregnancy or breast feeding, male partners of pregnant females. Inability to understand the Protocol or follow its instructions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03730311
Contact: Tapanee Mahasanprasert | +66(0) 2 412-1315 | tapanee.mahasanprasert@aclires.com |
Thailand | |
Siriraj Hospital | |
Bangkok, Thailand | |
Contact: Somruedee Chatsiricharoenkul, Assoc. Prof., MD +66 (0)2 412 1315 |
Principal Investigator: | Somruedee Chatsiricharoenkul, Assoc. Prof., MD | Siriraj Hospital Bangkok, Thailand |
Responsible Party: | Viriom |
ClinicalTrials.gov Identifier: | NCT03730311 |
Other Study ID Numbers: |
HIV-VM1500-11 |
First Posted: | November 5, 2018 Key Record Dates |
Last Update Posted: | May 20, 2019 |
Last Verified: | May 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Genital Diseases Urogenital Diseases Immunologic Deficiency Syndromes Immune System Diseases Elsulfavirine Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |